ADVANCES IN PHARMACOLOGICAL THERAPY FOR URINARY TRACT INFECTIONS: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v5i3.4995Keywords:
Urinary tract infections, pharmacological therapy, advances.Abstract
Introduction: Urinary tract infections (UTIs) represent a global challenge, impacting quality of life and generating significant costs. Antimicrobial resistance increases the complexity of conventional antibiotic treatment. The search for innovative therapies is crucial to tackling this problem. Objective: This review analyzes recent advances in pharmacological therapy for UTIs, highlighting new antimicrobial agents and non-antibiotic therapies. We also explore advanced diagnostics, multidisciplinary approaches and the impact of the COVID-19 pandemic on UTIs. Challenges in specific populations, ethical and economic considerations, as well as prevention strategies, urinary microbiota and precision medicine are discussed. Methods: We conducted a literature review of the last 15 years, including original studies and reviews. Inclusion criteria included new therapies, antimicrobial agents and advances in diagnosis. The search involved PubMed, Web of Science, Scopus and Google Scholar. The final sample comprised studies relevant to the pharmacological therapy of UTIs. Results and Discussion: Advances in new antimicrobial agents, non-antibiotic therapies and molecular diagnostics stand out. Multidisciplinary and collaborative strategies have shown benefits, while the COVID-19 pandemic has impacted treatment patterns. Conclusion: Despite progress, persistent challenges include antimicrobial resistance, ethical and economic issues. Investing in research, prevention strategies and precision medicine is crucial to optimize the clinical management of UTIs. This review highlights the continued need for innovation in the approach to UTIs, aiming to benefit individuals and global public health.
Downloads
References
ACKLEY, Renee et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrobial agents and chemotherapy, v. 64, n. 5, p. 10.1128/aac. 02313-19, 2020. DOI: https://doi.org/10.1128/AAC.02313-19
ALBIN, Owen R.; PATEL, Twisha S.; KAYE, Keith S. Meropenem–vaborbactam for adults with complicated urinary tract and other invasive infections. Expert Review of Anti-infective Therapy, v. 16, n. 12, p. 865-876, 2018. DOI: https://doi.org/10.1080/14787210.2018.1542300
BADER, Mazen S. et al. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgraduate medicine, v. 132, n. 3, p. 234-250, 2020. DOI: https://doi.org/10.1080/00325481.2019.1680052
CHU, Christine M.; LOWDER, Jerry L. Diagnosis and treatment of urinary tract infections across age groups. American journal of obstetrics and gynecology, v. 219, n. 1, p. 40-51, 2018. DOI: https://doi.org/10.1016/j.ajog.2017.12.231
DHILLON, Sohita. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs, v. 78, p. 1259-1270, 2018. DOI: https://doi.org/10.1007/s40265-018-0966-7
DUNNE, Michael W. et al. Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial. Clinical Infectious Diseases, v. 76, n. 1, p. 78-88, 2023. DOI: https://doi.org/10.1093/cid/ciac704
FISHER, Holly et al. “Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.” The Lancet. Infectious diseases, v. 18, n. 9, 2018. DOI: https://doi.org/10.1016/S1473-3099(18)30279-2
GHOURI, Flavia; HOLLYWOOD, Amelia; RYAN, Kath. A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy. BMC pregnancy and childbirth, v. 18, n. 1, p. 1-10, 2018. DOI: https://doi.org/10.1186/s12884-018-1732-2
MAJEED, Aneela et al. An update on emerging therapies for urinary tract infections. Expert Opinion on Emerging Drugs, v. 22, n. 1, p. 53-62, 2017. DOI: https://doi.org/10.1080/14728214.2017.1293650
MCATEER, John et al. Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated bacteremia. Clinical Infectious Diseases, v. 76, n. 9, p. 1604-1612, 2023. DOI: https://doi.org/10.1093/cid/ciad009
MONTINI, Giovanni et al. Short oral antibiotic therapy for pediatric febrile urinary tract infections: a randomized trial. Pediatrics, v. 153, n. 1, 2024. DOI: https://doi.org/10.1542/peds.2023-062598
TAN, Chee Wei; CHLEBICKI, Maciej Piotr. Urinary tract infections in adults. Singapore medical journal, v. 57, n. 9, p. 485, 2016. DOI: https://doi.org/10.11622/smedj.2016153
VAZOURAS, Konstantinos et al. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections. Journal of global antimicrobial resistance, v. 20, p. 4-10, 2020. DOI: https://doi.org/10.1016/j.jgar.2019.06.016
WILLIAMS, Gabrielle et al. Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews, n. 11, 2023. DOI: https://doi.org/10.1002/14651858.CD001321.pub7
XIA, Jia-yue et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One, v. 16, n. 9, p. e0256992, 2021. DOI: https://doi.org/10.1371/journal.pone.0256992
Downloads
Published
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
